MAY 28, 2015 3:47 PM PDT

Herpes-based therapy shows promise for melanoma treatment

WRITTEN BY: Robert Woodard
Melanoma cells: Image shows podosomes (yellow), cell nuclei (blue), actin (red), and an actin regulator (green).A phase III clinical trial has demonstrated the therapeutic benefit of the oncolytic virus Talimogene Laherparepvec (T-VEC) against melanoma, paving the way for a potential novel therapy for patients with metastatic melanoma. T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial.

T-VEC preferentially kills cancer cells. It is based on a cancer-killing herpes virus that has been genetically modified to prevent it from producing the protein that allows it to infect healthy cells. Instead, the virus thrives on a similar version of that protein produced by cancer cells. Inside the cancer cells, the virus selectively multiplies, causing the cancer cells burst open. The virus then spills out into the surrounding area and triggers an enhanced anti-tumor immune response.

Once the immune response has been triggered by T-VEC, it apparently starts to detect and attack cancer throughout the body. The reasons for this are not completely clear, the results of the trial confirmed the effect-even tumors that had not been directly infected by the virus got smaller or disappeared.

In the randomized open-label phase III trial, T-VEC was compared with granulocyte macrophage colony-stimulating factor (GM-CSF) in patients with unresected stage IIIB to IV melanoma. Among the 423 individuals who participated in the trial, 25% responded to the treatment and 16% were still in remission after six months. About 10% of the patients treated had "complete remission," with no detectable cancer remaining.

T-VEC therapy is given by injection. Patients in the trial received a dose every two weeks for up to 18 months. The most common adverse events (AEs) with T-VEC were fatigue, chills, and pyrexia (fever). The only grade 3 or 4 AE occurring in ? 2% of T-VEC-treated patients was cellulitis (2.1%). No fatal treatment-related AEs occurred.

The results indicate that T-VEC has the potential to treat cancer even when the disease has spread to organs throughout the body.

According to Kevin Harrington, professor of biological cancer therapies at the Institute of Cancer Research London who led the work: "This is the big promise of this treatment. It's the first time a virotherapy has been shown to be successful in a phase III trial."

According to scientists, if approved T-VEC could possibly be more widely available for cancer patients by next year.

The study was published in the May 26, 2015 issue of the Journal of Clinical Oncology.

According to the American Cancer Society, in 2015 about 73,870 new melanomas will be diagnosed (about 42,670 in men and 31,200 in women) in the US. The survival rate of stage IIIB and IIIC is around 40% to 59%. The survival rate for stage IV is around 15% to 20%.

(Sources: theguardian.com, Journal of Clinical Oncology, American Cancer Society)
About the Author
You May Also Like
JAN 17, 2021
Immunology
A Single Dose Nanoparticle Vaccine for COVID-19
JAN 17, 2021
A Single Dose Nanoparticle Vaccine for COVID-19
In the race for finding the right vaccine for the COVID-19 pandemic, a new vaccine candidate emerged. Researchers at Sta ...
JAN 19, 2021
Immunology
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
JAN 19, 2021
Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefire
Milk, eggs, peanuts, tree nuts, wheat, soy, fish, and shellfish—these foods are among the most unwanted list for t ...
JAN 26, 2021
Immunology
COVID Vaccine Reactions: You're As Likely to Be Struck by Lightning
JAN 26, 2021
COVID Vaccine Reactions: You're As Likely to Be Struck by Lightning
In a period of just over three weeks, over four million people received Moderna’s COVID-19 vaccine. Out of all the ...
MAR 04, 2021
Immunology
Why Do We Need Two Shots of the COVID Vaccine?
MAR 04, 2021
Why Do We Need Two Shots of the COVID Vaccine?
Unlike social distancing, mask-wearing, and hand hygiene, vaccines are our best bet as a long-term solution to protectin ...
APR 13, 2021
Immunology
Food-borne Fungus Impedes Gut Healing
APR 13, 2021
Food-borne Fungus Impedes Gut Healing
In a recent study, researchers discovered that a fungus present in cheese, processed meats, beer, and other fermented fo ...
APR 27, 2021
Neuroscience
Leaky Blood-Brain Barrier Linked to Schizophrenia
APR 27, 2021
Leaky Blood-Brain Barrier Linked to Schizophrenia
Researchers from the University of Pennsylvania have found that people with schizophrenia may have a more permeable bloo ...
Loading Comments...